E. Demidova, Randy Lesh, V. Avkshtol, M. Einarson, E. Golemis, S. Arora, J. Meyer
{"title":"Abstract 349: Association of DNA damage response capacity with neoadjuvant chemoradiation response in locally advanced rectal cancer","authors":"E. Demidova, Randy Lesh, V. Avkshtol, M. Einarson, E. Golemis, S. Arora, J. Meyer","doi":"10.1158/1538-7445.AM2021-349","DOIUrl":null,"url":null,"abstract":"Background: Locally advanced rectal cancer (RC) cases are ~60% of newly diagnosed RCs, with neoadjuvant chemoradiation therapy (nCRT) followed by surgery as the standard of care. While nCRT is highly toxic, it is also beneficial. Recent prospective trials reported that up to 59% locally advanced RC cases exhibit complete clinical response, suggesting these patients as ideal candidates for organ preservation. However, currently there is no biomarker to predict who will or will not benefit from nCRT. The goal of this study was to establish a predictive biomarker for benefit from nCRT, based on the hypothesis that inherent DNA damage response (DDR) capacity contributes to nCRT response in RC. Methods: To gain insight into inherent DDR capacity, we profiled primary peripheral blood lymphocytes (pPBLs) from RC patients by quantitative immunofluorescence, Luminex-multianalyte assay, and pPBL DNA whole exome sequencing (WES). RC patients analyzed were segregated by neoadjuvant rectal (NAR) score: NAR 14, poor responders (PoRs), n=21; 1 Results: pPBLs from CRs showed significantly elevated γH2AX foci (a hallmark of double strand breaks) vs. PoRs (P 0.082 as a cutpoint, we could include 90% patients with a CR. Finally, WES analysis of pPBL DNA from 15 CRs and 15 PoRs revealed that CRs were enriched in predicted-pathogenic variants in base excision repair genes vs. PoRs (p Conclusion and future work: Overall, our data suggests inherent DDR capacity testing may predict the magnitude of benefit from nCRT and assist in patient selection for treatment. Validation in a larger RC patient population is needed to confirm these findings. Biological studies testing the impact of the identified variants in base excision repair on inherent DDR capacity are warranted. Citation Format: Elena V. Demidova, Randy W. Lesh, Vladimir Avkshtol, Margret B. Einarson, Erica A. Golemis, Sanjeevani Arora, Joshua E. Meyer. Association of DNA damage response capacity with neoadjuvant chemoradiation response in locally advanced rectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 349.","PeriodicalId":10518,"journal":{"name":"Clinical Research (Excluding Clinical Trials)","volume":"58 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Research (Excluding Clinical Trials)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1538-7445.AM2021-349","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Locally advanced rectal cancer (RC) cases are ~60% of newly diagnosed RCs, with neoadjuvant chemoradiation therapy (nCRT) followed by surgery as the standard of care. While nCRT is highly toxic, it is also beneficial. Recent prospective trials reported that up to 59% locally advanced RC cases exhibit complete clinical response, suggesting these patients as ideal candidates for organ preservation. However, currently there is no biomarker to predict who will or will not benefit from nCRT. The goal of this study was to establish a predictive biomarker for benefit from nCRT, based on the hypothesis that inherent DNA damage response (DDR) capacity contributes to nCRT response in RC. Methods: To gain insight into inherent DDR capacity, we profiled primary peripheral blood lymphocytes (pPBLs) from RC patients by quantitative immunofluorescence, Luminex-multianalyte assay, and pPBL DNA whole exome sequencing (WES). RC patients analyzed were segregated by neoadjuvant rectal (NAR) score: NAR 14, poor responders (PoRs), n=21; 1 Results: pPBLs from CRs showed significantly elevated γH2AX foci (a hallmark of double strand breaks) vs. PoRs (P 0.082 as a cutpoint, we could include 90% patients with a CR. Finally, WES analysis of pPBL DNA from 15 CRs and 15 PoRs revealed that CRs were enriched in predicted-pathogenic variants in base excision repair genes vs. PoRs (p Conclusion and future work: Overall, our data suggests inherent DDR capacity testing may predict the magnitude of benefit from nCRT and assist in patient selection for treatment. Validation in a larger RC patient population is needed to confirm these findings. Biological studies testing the impact of the identified variants in base excision repair on inherent DDR capacity are warranted. Citation Format: Elena V. Demidova, Randy W. Lesh, Vladimir Avkshtol, Margret B. Einarson, Erica A. Golemis, Sanjeevani Arora, Joshua E. Meyer. Association of DNA damage response capacity with neoadjuvant chemoradiation response in locally advanced rectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 349.
背景:局部晚期直肠癌(RC)病例约占新诊断直肠癌的60%,以新辅助放化疗(nCRT)后手术为标准治疗。虽然nCRT有剧毒,但它也是有益的。最近的前瞻性试验报道,高达59%的局部晚期RC病例表现出完全的临床反应,这表明这些患者是器官保存的理想候选者。然而,目前还没有生物标志物来预测谁会或不会从nCRT中受益。本研究的目的是基于固有DNA损伤反应(DDR)能力有助于RC中nCRT反应的假设,建立一种预测nCRT益处的生物标志物。方法:为了深入了解内在的DDR能力,我们通过定量免疫荧光、luminex多分析物测定和pPBL DNA全外显子组测序(WES)对RC患者的原发性外周血淋巴细胞(pPBL)进行了分析。分析的RC患者按新辅助直肠(NAR)评分进行分离:NAR 14,不良反应(PoRs), n=21;结果:来自CRs的pPBL比来自prs的pPBL显示出显著升高的γ - h2ax灶(双链断裂的标志)(P为0.082作为切入点,我们可以包括90%的CR患者)。最后,来自15个CRs和15个prs的pPBL DNA的WES分析显示,CRs与来自prs的pPBL DNA相比,在碱基切除修复基因的预测致病性变异中富集(P)。总的来说,我们的数据表明,内在DDR能力测试可以预测nCRT的获益程度,并有助于患者选择治疗方案。需要在更大的RC患者群体中进行验证以证实这些发现。生物学研究测试在碱基切除修复中确定的变异对固有DDR能力的影响是有必要的。引文格式:Elena V. Demidova, Randy W. Lesh, Vladimir Avkshtol, margaret B. Einarson, Erica A. Golemis, Sanjeevani Arora, Joshua E. Meyer。局部晚期直肠癌DNA损伤反应能力与新辅助放化疗反应的关系[摘要]。见:美国癌症研究协会2021年年会论文集;2021年4月10日至15日和5月17日至21日。费城(PA): AACR;癌症杂志,2021;81(13 -增刊):349。